Galmed initiates its Phase I study of Aramchol, its drug candidate for Fatty Liver Disease .

This double blind, placebo controlled phase-I trial that has been initiated at the Tel-Aviv Sourasky Medical Center (Tel-Aviv, Israel) is designed to assess and characterize the safety and tolerability of Aramchol in healthy male subjects at single doses and subsequently in overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses. It is also aimed at assessing the pharmacokinetics of Aramchol at the administered doses and to characterize the drug effect on lipid profile and functional pharmacodynamics following single and multiple dose administrations.

Back to Top